Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs

The present study has evaluated the protection conferred by a single subcutaneous dose of a modified vaccinia virus Ankara (MVA) vectored vaccine encoding the Rift Valley Fever virus (RVFV) glycoproteins Gn and Gc in lambs. Three groups of six to seven lambs were immunized as follows one group received the vaccine (termed rMVA-GnGc), a second group received an MVA vector (vector control) and a third group received saline solution (non-vaccinated control). Fourteen days later, all animals were subcutaneously challenged with 10 5 TCID50 of the virulent RVFV isolate 56/74 and vaccine efficacy assessed using standard endpoints. Two lambs (one from the vaccine group and one from the vector control group) succumbed to RVFV challenge, showing characteristic liver lesions. Lambs from both the vector control and non-vaccinated groups were febrile from days 2 to 5 post challenge (pc) while those in the rMVA-GnGc group showed a single peak of pyrexia at day 3 pc. RVFV RNA was detected in both nasal and oral swabs from days 3 to 7 pc in some lambs from the vector control and non-vaccinated groups, but no viral shedding could be detected in the surviving lambs vaccinated with rMVA-GnGc. Together, the data suggest that a single dose of the rMVA-GnGc vaccine may be sufficient to reduce RVFV shedding and duration of viremia but does not provide sterile immunity nor protection from disease. Further optimization of this vaccine approach in lambs is warranted. © 2014 Elsevier B.V. All rights reserved.

Saved in:
Bibliographic Details
Main Authors: Busquets, N., Lorenzo Alguacil, Gema, López-Gil, E., Rivas, R., Solanes, D., Galindo-Cardiel, I., Abad, F. X., Rodríguez, F., Bensaid, A., Warimwe, G., Gilbert, S. C., Domingo, M., Brun Torres, Alejandro
Format: artículo biblioteca
Language:English
Published: Elsevier 2014
Subjects:Rift Valley Fever virus, MVA vaccine, Sheep experimental infection, GnGc glycoproteins, Virus shedding,
Online Access:http://hdl.handle.net/20.500.12792/5007
http://hdl.handle.net/10261/290025
Tags: Add Tag
No Tags, Be the first to tag this record!
id dig-inia-es-10261-290025
record_format koha
spelling dig-inia-es-10261-2900252023-02-17T08:26:37Z Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs Busquets, N. Lorenzo Alguacil, Gema López-Gil, E. Rivas, R. Solanes, D. Galindo-Cardiel, I. Abad, F. X. Rodríguez, F. Bensaid, A. Warimwe, G. Gilbert, S. C. Domingo, M. Brun Torres, Alejandro Rift Valley Fever virus MVA vaccine Sheep experimental infection GnGc glycoproteins Virus shedding The present study has evaluated the protection conferred by a single subcutaneous dose of a modified vaccinia virus Ankara (MVA) vectored vaccine encoding the Rift Valley Fever virus (RVFV) glycoproteins Gn and Gc in lambs. Three groups of six to seven lambs were immunized as follows one group received the vaccine (termed rMVA-GnGc), a second group received an MVA vector (vector control) and a third group received saline solution (non-vaccinated control). Fourteen days later, all animals were subcutaneously challenged with 10 5 TCID50 of the virulent RVFV isolate 56/74 and vaccine efficacy assessed using standard endpoints. Two lambs (one from the vaccine group and one from the vector control group) succumbed to RVFV challenge, showing characteristic liver lesions. Lambs from both the vector control and non-vaccinated groups were febrile from days 2 to 5 post challenge (pc) while those in the rMVA-GnGc group showed a single peak of pyrexia at day 3 pc. RVFV RNA was detected in both nasal and oral swabs from days 3 to 7 pc in some lambs from the vector control and non-vaccinated groups, but no viral shedding could be detected in the surviving lambs vaccinated with rMVA-GnGc. Together, the data suggest that a single dose of the rMVA-GnGc vaccine may be sufficient to reduce RVFV shedding and duration of viremia but does not provide sterile immunity nor protection from disease. Further optimization of this vaccine approach in lambs is warranted. © 2014 Elsevier B.V. All rights reserved. 2023-02-17T08:26:37Z 2023-02-17T08:26:37Z 2014 artículo Antiviral Research 108: 165-172 (2014) 0166-3542 http://hdl.handle.net/20.500.12792/5007 http://hdl.handle.net/10261/290025 10.1016/j.antiviral.2014.05.020 1872-9096 en none Elsevier
institution INIA ES
collection DSpace
country España
countrycode ES
component Bibliográfico
access En linea
databasecode dig-inia-es
tag biblioteca
region Europa del Sur
libraryname Biblioteca del INIA España
language English
topic Rift Valley Fever virus
MVA vaccine
Sheep experimental infection
GnGc glycoproteins
Virus shedding
Rift Valley Fever virus
MVA vaccine
Sheep experimental infection
GnGc glycoproteins
Virus shedding
spellingShingle Rift Valley Fever virus
MVA vaccine
Sheep experimental infection
GnGc glycoproteins
Virus shedding
Rift Valley Fever virus
MVA vaccine
Sheep experimental infection
GnGc glycoproteins
Virus shedding
Busquets, N.
Lorenzo Alguacil, Gema
López-Gil, E.
Rivas, R.
Solanes, D.
Galindo-Cardiel, I.
Abad, F. X.
Rodríguez, F.
Bensaid, A.
Warimwe, G.
Gilbert, S. C.
Domingo, M.
Brun Torres, Alejandro
Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs
description The present study has evaluated the protection conferred by a single subcutaneous dose of a modified vaccinia virus Ankara (MVA) vectored vaccine encoding the Rift Valley Fever virus (RVFV) glycoproteins Gn and Gc in lambs. Three groups of six to seven lambs were immunized as follows one group received the vaccine (termed rMVA-GnGc), a second group received an MVA vector (vector control) and a third group received saline solution (non-vaccinated control). Fourteen days later, all animals were subcutaneously challenged with 10 5 TCID50 of the virulent RVFV isolate 56/74 and vaccine efficacy assessed using standard endpoints. Two lambs (one from the vaccine group and one from the vector control group) succumbed to RVFV challenge, showing characteristic liver lesions. Lambs from both the vector control and non-vaccinated groups were febrile from days 2 to 5 post challenge (pc) while those in the rMVA-GnGc group showed a single peak of pyrexia at day 3 pc. RVFV RNA was detected in both nasal and oral swabs from days 3 to 7 pc in some lambs from the vector control and non-vaccinated groups, but no viral shedding could be detected in the surviving lambs vaccinated with rMVA-GnGc. Together, the data suggest that a single dose of the rMVA-GnGc vaccine may be sufficient to reduce RVFV shedding and duration of viremia but does not provide sterile immunity nor protection from disease. Further optimization of this vaccine approach in lambs is warranted. © 2014 Elsevier B.V. All rights reserved.
format artículo
topic_facet Rift Valley Fever virus
MVA vaccine
Sheep experimental infection
GnGc glycoproteins
Virus shedding
author Busquets, N.
Lorenzo Alguacil, Gema
López-Gil, E.
Rivas, R.
Solanes, D.
Galindo-Cardiel, I.
Abad, F. X.
Rodríguez, F.
Bensaid, A.
Warimwe, G.
Gilbert, S. C.
Domingo, M.
Brun Torres, Alejandro
author_facet Busquets, N.
Lorenzo Alguacil, Gema
López-Gil, E.
Rivas, R.
Solanes, D.
Galindo-Cardiel, I.
Abad, F. X.
Rodríguez, F.
Bensaid, A.
Warimwe, G.
Gilbert, S. C.
Domingo, M.
Brun Torres, Alejandro
author_sort Busquets, N.
title Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs
title_short Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs
title_full Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs
title_fullStr Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs
title_full_unstemmed Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs
title_sort efficacy assessment of an mva vectored rift valley fever vaccine in lambs
publisher Elsevier
publishDate 2014
url http://hdl.handle.net/20.500.12792/5007
http://hdl.handle.net/10261/290025
work_keys_str_mv AT busquetsn efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs
AT lorenzoalguacilgema efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs
AT lopezgile efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs
AT rivasr efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs
AT solanesd efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs
AT galindocardieli efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs
AT abadfx efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs
AT rodriguezf efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs
AT bensaida efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs
AT warimweg efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs
AT gilbertsc efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs
AT domingom efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs
AT bruntorresalejandro efficacyassessmentofanmvavectoredriftvalleyfevervaccineinlambs
_version_ 1767603037944152064